Hisun Pharmaceutical Receives IND Application Acceptance for HSK60002 on July 13

According to Jin10, Hisun Pharmaceutical received an IND application acceptance notification from China's National Medical Products Administration on July 13 for HSK60002 tablet, a self-developed oral small-molecule drug candidate for inflammatory diseases classified as a novel chemical drug. Preclinical research showed significant efficacy activity in relevant animal models.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments